Abstract
The exclusion of chronic kidney disease (CKD) patients from clinical trials-particularly cardiovascular trials-remains a long-standing, unsolved problem, which prevents the optimization of clinical care in these patients. The situation recalls the insufficient recruitment of women in cardiovascular trials until the 1980s, a problem that was only resolved following regulatory interventions. Regulatory agencies are in a unique position to promote recruitment of CKD patients in clinical trials. The main stakeholders, namely patients' associations and scientific societies, should make major lobbying efforts to persuade these agencies that the issue is an absolute public health priority.
Original language | English |
---|---|
Pages (from-to) | 1112-1114 |
Number of pages | 3 |
Journal | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association |
Volume | 34 |
Issue number | 7 |
Early online date | 27 Feb 2019 |
DOIs | |
Publication status | Published - Jul 2019 |
Keywords
- CKD
- Cardiovascular
- Clinical trial
- Diabetes mellitus
- Guidelines
- clinical trial
- guidelines
- diabetes mellitus
- cardiovascular